- Oral Presentation to Highlight Data from Phase II Study Evaluating Bavituximab in Advanced Breast Cancer -
- Poster Presentation to Discuss Data from Phase I Study Evaluating Bavituximab in Multiple Tumor Types -
TUSTIN, Calif., May 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that data from two ongoing clinical trials assessing its lead compound bavituximab for the treatment of cancer will be discussed at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. Preliminary data from a Phase II clinical trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients will be the subject of an oral presentation at 10:30 AM EDT on June 1, 2009. A second presentation detailing preliminary results from a Phase I clinical trial evaluating bavituximab as solo therapy in patients with advanced refractory cancer will be discussed in a poster session from 1:00 PM to 5:00 PM EDT, also on June 1, 2009.
Bavituximab Presentation Details: Title: Phase II study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer. Authors: D. Tabagari, G. Nemsadze, M. Jincharadze, M. Janjalia, J. Shan Time: Monday June 1, 10:30 AM Location: Level 4, Valencia Room, W415A Abstract No: 3005 Title: Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: Preliminary results. Authors: N. K. Ibrahim, L. Wong, L. Rosen, J. Shan Time: Monday June 1, 1:00 PM to 5:00 PM Location: Level 2, West Hall C Abstract No: 1080
Bavituximab is a monoclonal anti
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved